8 articles tagged with "biotech"
A small biotech firm has ceased operations following a significant delay in securing FDA approval for its clinical trial plan, highlighting the critical nature of regulatory timelines.
Smaller biotech firms are initiating discussions with the Trump administration as the sector experiences notable mergers and acquisitions, while addressing trust issues in healthcare.
Psychedelic biotech companies are facing increased regulatory scrutiny, coinciding with acquisition efforts from Biogen and Eli Lilly, while Gilead faces criticism from Doctors Without Borders.
Amid intensifying competition, U.S. venture capital firms are adapting their strategies by investing directly in upstream scientific pipelines within China's biotech sector.
The White House has initiated discussions on drug pricing reforms by sharing drafted legislative text with major pharmaceutical companies, while also addressing Chinese biotech licensing.
China's rapidly growing biotech sector is reshaping international scientific collaboration, particularly in light of recent NIH actions that may hinder partnerships.
Eli Lilly underscores the critical role of GLP-1 medications in healthcare, while also noting Merck's acquisition of Terns Pharma and other biotech advancements.
A fund has allocated $200 million to a biotech stock that experienced a 30% increase following positive Phase 3 clinical trial results, indicating robust market confidence.